CLINICAL ADVANCES: INDIVIDUALIZING TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA

Released On
August 08, 2019

Expires On
August 08, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Oncology, Hematology

Topic(s)
Leukemia

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Albert Einstein College of Medicine.


Supported by an educational grant from Pharmacyclics, LLC..

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours (.75 pharmacology).

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

Oncology, Hematology, and other clinicians that care for patients with CLL.

Program Overview

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries. In 2018, there will be an estimated 20,940 new cases of CLL diagnosed and an estimated 4,510 deaths. CLL is a chronic and generally incurable disease with the average patient receiving multiple lines of therapy throughout their disease course. The treatment goal of CLL is long-term remission and the choice of treatment depends on stage, risk status, and the patient’s overall health. Achieving long-term remission typically requires combination of chemotherapy plus targeted therapies, and stem cell transplant or clinical trials for select high-risk recurrence patients.

Fortunately, the treatment of CLL is one of the most active areas of recent clinical research. There is not one standardized approach for treating patients with CLL.

This activity will examine real-world evidence of treatment practice patterns, and patient outcomes will shed significant light on how hematologists can best personalize treatment to maximize overall survival and patient quality of life.

This webcast was recorded live at the Conversations in Oncology Live Virtual Symposium 2019 and is being used with the permission of the presenters.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Use patient’s age, prognostic markers, comorbidities and patient’s preferences when individualizing CLL management
  • Utilize new and emerging therapies as well as chemo-immunotherapy for the appropriate patients with CLL
  • Understand the importance of degree of response to therapy, including U-MRD (undetectable Minimal Residual Disease), in managing care
  • Recognize and manage the common complications related to the medications used to treat CLL

Faculty

Noah Kornblum, MD

Assistant Professor, Department of Medicine (Oncology)
Bone Marrow Transplant/Heme Malignancy
Montefiore Einstein Center for Cancer Care
Bronx, NY

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd

Chief Medical Officer and Executive Vice President
CLL Society
Claremont, CA

Rasim A. Gucalp, MD, FACP

Course Director and Moderator
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Montefiore Medical Center
Director, Hematology/Oncology Fellowship Program
Bronx, NY

Physician Accreditation Statement

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222.

Credit Designation

This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.

Faculty Disclosure Policy

Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities.

The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship with a commercial interest*. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Faculty disclosures are provided below.

*The ACCME defines a commercial interest as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providing clinical service directly to patients to be commercial interests - unless the provider of the clinical service is owned, or controlled by, an ACCME-defined commercial interest.

Dr. Gucalp

  • Has no relevant conflicts of interest with any ACCME-defined commercial interest.

Dr. Koffman

  • Consulting Fee: Janssen, Novartis, and Verastem Oncology
  • Ownership Interest: Abbvie, AstraZeneza, BeiGene, Bristol-Myers Squibb, Celgene, Gilead Sciences, Inc., Johnson & Johnson, MEI Pharma Inc, Miragen Therapeutics Inc, Portola Pharmaceuticals Inc, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc, and Verastem Oncology.

Dr. Koffman has indicated that his reported relationships will not impact his ability to present an unbiased presentation.

Dr. Kornblum has no relevant conflicts of interest with any ACCME-defined commercial interest.

Planning Committee:

Gregg Sherman, MD, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Josh Kilbridge, Medical Writer, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Michelle Frisch, MPH, Activity Planning Committe, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Daniela Hiedra, BA, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Sandy Bihlmeyer, MEd, Activity Planning Committee, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine or the National Association for Continuing Education. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.